The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Saved in:
| Title: | The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. |
|---|---|
| Authors: | Farraye, Francis A.1 (AUTHOR) farraye.francis@mayo.edu, Qazi, Taha2 (AUTHOR), Kotze, Paulo G.3 (AUTHOR), Moore, Gregory T.4,5 (AUTHOR), Mundayat, Rajiv6 (AUTHOR), Lawendy, Nervin7 (AUTHOR), Sharma, Puza P.6 (AUTHOR), Judd, Donna T.7 (AUTHOR) |
| Source: | Alimentary Pharmacology & Therapeutics. Aug2021, Vol. 54 Issue 4, p429-440. 12p. 4 Charts, 4 Graphs. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
